Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Infectious Disease/HIV

Infectious Disease

HIV

37

Pipeline Programs↗

172

Active Trials↗

24

Companies Involved↗

HIV is a moderately active landscape with 37 programs across 24 companies. The most active players are Incyte, Jiangsu Hansoh Pharmaceutical Co., Ltd., GSK. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

86/100

Mech. Concentration

20/100

Completion Rate

91/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Incyte

1 program

Jiangsu Hansoh Pharmaceutical Co., Ltd.

1 program

GSK

1 program

Pipeline

Programs by Phase

Preclinical11

Eplerenone and Lifestyle

Massachusetts General Hospital

Lymphocytes, Activated

National Institute of Allergy and Infectious Diseases (NIAID)

GVHD Prophylaxis

National Cancer Institute (NCI)

Plerixafor

Genzyme, a Sanofi Company

Thymopentin

Immunobiology Research Institute

Phase 15

CAB LA

GSK

DV201P-RNA

National Institute of Allergy and Infectious Diseases (NIAID)

DV202B1-RNA

National Institute of Allergy and Infectious Diseases (NIAID)

Epgt121v1-LS (IV)

National Institute of Allergy and Infectious Diseases (NIAID)

Epgt121v1-LS (SC)

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 213

Alimatravir

Merck & Co.

Maraviroc

GSK

PGDM1400LS

National Institute of Allergy and Infectious Diseases (NIAID)

VRC07-523LS

National Institute of Allergy and Infectious Diseases (NIAID)

PGT121.414.LS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 38

Cystine

University of Chicago

INCMGA00012

Incyte

Emtricitabine/tenofovir

GSK

INCB106385

Incyte

HS-10356

Merck & Co.

Approved

No programs

Analysis

Modality Breakdown

93%

Small molecule

25 of 27 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 86% of 37 pipeline programs.

Analysis

Trial Status

429

clinical trials

Completed219 · 51%

Recruiting78 · 18%

Not yet recruiting52 · 12%

Active, not recruiting35 · 8%

Terminated15 · 3%

Unknown status15 · 3%

Other15 · 3%

Clinical Trials

Trial Activity

429 trials

Olfactory Function and Model-based Behavior in People Living With HIV and SUD

Recruiting·National Institute on Drug Abuse (NIDA)·N/A·NCT07637669·120 enrolled

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05470491·265 enrolled

Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07468695·300 enrolled

Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00789009·600 enrolled

Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07645352·300 enrolled

Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07645378·200 enrolled

Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07390916·300 enrolled

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05419024·50 enrolled

Hybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Adolescents and Young Adults (Project IMPACT)

Recruiting·WWestat·Preclinical·NCT06444360·360 enrolled

Describe and Evaluate the Impact of Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75 Who Are Being Treated at Nice University Hospital.

Recruiting·CCentre Hospitalier Universitaire de Nice·Preclinical·NCT07388394·136 enrolled

Syndemic Triple HIV/HBV/HCV Virus Screening Via EMR Automation at Primary Care Clinics

Recruiting·UUniversity of Texas Southwestern Medical Center·Preclinical·NCT07031219·50 enrolled

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001281·2,419 enrolled

Development and Evaluation of a Multi-Component Intervention to Support HIV Care Engagement Among Patients Receiving Cancer Treatment in Zimbabwe

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT06934369·300 enrolled

Phase 2b Clinical Trial Using Multiple Interventions With Distinct Anti-Reservoir Activities In People On Antiretroviral Treatment

Recruiting·FFederal University of São Paulo·Phase 2·NCT07903441·70 enrolled

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00039689·750 enrolled

Page 1 of 29

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)